FHTX
NASDAQ · Biotechnology
Foghorn Therapeutics Inc
$5.21
+0.21 (+4.20%)
Financial Highlights (FY 2026)
Revenue
24.08M
Net Income
-92,266,448
Gross Margin
—
Profit Margin
-383.2%
Rev Growth
+157.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 35.6% | 35.6% | 35.6% |
| Operating Margin | -454.3% | 5.1% | 5.1% | 4.9% |
| Profit Margin | -383.2% | 5.2% | 4.9% | 5.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.08M | 275.09M | 271.86M | 230.16M |
| Gross Profit | — | 98.02M | 96.87M | 82.01M |
| Operating Income | -109,376,749 | 13.90M | 13.80M | 11.27M |
| Net Income | -92,266,448 | 14.43M | 13.33M | 11.49M |
| Gross Margin | — | 35.6% | 35.6% | 35.6% |
| Operating Margin | -454.3% | 5.1% | 5.1% | 4.9% |
| Profit Margin | -383.2% | 5.2% | 4.9% | 5.0% |
| Rev Growth | +157.8% | -4.2% | -6.6% | +8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 171.65M | 139.92M | 178.86M |
| Total Equity | — | 251.92M | 241.00M | 245.51M |
| D/E Ratio | — | 0.68 | 0.58 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -101,617,066 | 18.56M | 20.13M | 16.16M |
| Free Cash Flow | — | 14.99M | 11.27M | 12.60M |